Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D001900:Boston / Q000453:epidemiology; D016022:Case-Control Studies; D015986:Confounding Factors, Epidemiologic; D003237:Connecticut / Q000453:epidemiology; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006689:Hodgkin Disease / Q000453:epidemiology* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism*; D016017:Odds Ratio; D015995:Prevalence; D012042:Registries; D012107:Research Design; D018570:Risk Assessment; D015983:Selection Bias
D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D016328:NF-kappa B; D001241:Aspirin